Key result
Occult transthyretin amyloidosis is detected in ~14% of elderly patients undergoing TAVR.
Why the study?
What is the prevalence of occult cardiac transthyretin amyloidosis detected by 99mTc-DPD bone scintigraphy in elderly patients with severe aortic stenosis referred for TAVR?
Cohort (n=101)
No
What is the prevalence of occult cardiac transthyretin amyloidosis detected by 99mTc-DPD bone scintigraphy in elderly patients with severe aortic stenosis referred for TAVR?
Approximately 1 in 7 elderly patients referred for TAVR have occult cardiac transthyretin amyloidosis (13.9%), with similar prevalence in men and women, which may impact clinical presentation and procedural outcomes.
Answers are grounded in this paper and cite their sources.
May warrant prospective ATTR screening evaluation in elderly TAVR candidates; extends prevalence data while leaving prognostic and management impact open.
is the most common valve disease in the developed world.Symptomatic severe
No takes yet. Share an insight, caveat, or question.
Scully et al. (2018) conducted a cohort in Severe aortic stenosis referred for TAVR (n=101). 99mTc-DPD bone scintigraphy screening for occult cardiac ATTR amyloidosis vs. DPD-negative patients (no cardiac ATTR amyloidosis) was evaluated on Prevalence of occult cardiac transthyretin amyloidosis (ATTR) diagnosed by 99mTc-DPD scintigraphy (95% CI 8%-22%). Occult cardiac transthyretin amyloidosis was diagnosed by 99mTc-DPD bone scintigraphy in 13.9% (95% CI 8%-22%) of elderly patients with severe aortic stenosis referred for TAVR.
Synapse has enriched 10 related papers. Consider them for comparative context: